The firm's core activities revolve around discovering and identifying innovative companies within the life sciences. This involves a proactive approach to sourcing opportunities that align with its investment thesis in bio-healthcare.
Beyond discovery, DAYLI Partners is also involved in building these companies, suggesting a hands-on approach to fostering growth and development. This engagement helps to mature early-stage ventures into more robust entities.
Ultimately, the firm's mandate includes investing in next-generation life science companies. This financial commitment is directed towards entities that are poised to make significant contributions to the bio-healthcare landscape, from research and development to new therapeutic solutions.
Headquartered in Seoul, South Korea, DAYLI Partners operates from a key hub for technological and medical innovation. Its geographical base allows it to tap into regional talent and opportunities within the life science ecosystem.
Through its focused investment strategy, DAYLI Partners aims to contribute to the evolution of the bio-healthcare industry by backing companies that are developing cutting-edge solutions and technologies.
